These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 32007151)

  • 1. Increased production and comprehensive guidelines needed for HPV vaccine.
    Phumaphi J; Gautam KC; Mason E;
    Lancet; 2020 Feb; 395(10221):319-321. PubMed ID: 32007151
    [No Abstract]   [Full Text] [Related]  

  • 2. Who should get the HPV vaccine? Usage expands amid debate.
    Peres J
    J Natl Cancer Inst; 2010 Jun; 102(12):838-40. PubMed ID: 20530765
    [No Abstract]   [Full Text] [Related]  

  • 3. Global HPV vaccination.
    Arie S
    BMJ; 2011 Feb; 342():d1042. PubMed ID: 21325382
    [No Abstract]   [Full Text] [Related]  

  • 4. Global human papillomavirus vaccination: can it be cost-effective?
    Crosbie EJ
    BJOG; 2012 Jan; 119(2):125-8. PubMed ID: 22168760
    [No Abstract]   [Full Text] [Related]  

  • 5. The new vaccine to prevent HPV.
    Lajiness MJ
    Urol Nurs; 2007 Apr; 27(2):153-4. PubMed ID: 17494457
    [No Abstract]   [Full Text] [Related]  

  • 6. The economic impact of HPV vaccines: not just cervical cancer.
    Myers ER
    Am J Obstet Gynecol; 2008 May; 198(5):487-8. PubMed ID: 18455522
    [No Abstract]   [Full Text] [Related]  

  • 7. Policy debate over human papillomavirus vaccines.
    Richman S
    J Low Genit Tract Dis; 2009 Apr; 13(2):128. PubMed ID: 19387138
    [No Abstract]   [Full Text] [Related]  

  • 8. Challenges of implementing human papillomavirus (HPV) vaccination policy.
    Raffle AE
    BMJ; 2007 Aug; 335(7616):375-7. PubMed ID: 17717366
    [No Abstract]   [Full Text] [Related]  

  • 9. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
    Gomez JA; Lepetic A; Demarteau N
    BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Towards global prevention of human papillomavirus-induced cancer.
    Roden RB; Gravitt P; Wu TC
    Eur J Immunol; 2008 Feb; 38(2):323-6. PubMed ID: 18228245
    [No Abstract]   [Full Text] [Related]  

  • 11. Economic analysis of HPV-vaccines: not so simple?
    Crott R
    Vaccine; 2007 Nov; 25(45):7717. PubMed ID: 17919785
    [No Abstract]   [Full Text] [Related]  

  • 12. IPVS statement on "Temporary HPV vaccine shortage: Implications globally to achieve equity".
    Garland SM; Stanley MA; Giuliano AR; Moscicki AB; Kaufmann A; Bhatla N; Woo YL;
    Papillomavirus Res; 2020 Jun; 9():100195. PubMed ID: 32205196
    [No Abstract]   [Full Text] [Related]  

  • 13. The Health Technology Assessment of bivalent HPV vaccine Cervarix in Italy.
    La Torre G; de Waure C; Chiaradia G; Mannocci A; Capri S; Ricciardi W
    Vaccine; 2010 Apr; 28(19):3379-84. PubMed ID: 20197141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
    de Kok IM; van Ballegooijen M; Habbema JD
    J Natl Cancer Inst; 2009 Aug; 101(15):1083-92. PubMed ID: 19571256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
    Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
    Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost and financing issues limit access to the HPV vaccine.
    Muthumariappan M; Raj GA
    Asian Pac J Cancer Prev; 2010; 11(2):573-4. PubMed ID: 20843155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human papillomavirus vaccination: where to now?
    Garland SM
    Sex Transm Infect; 2011 Dec; 87 Suppl 2(Suppl 2):ii23-4. PubMed ID: 22110148
    [No Abstract]   [Full Text] [Related]  

  • 18. Controlling cervical cancer.
    Bonati M; Garattini S
    Pharmacoeconomics; 2009; 27(2):91-3. PubMed ID: 19254043
    [No Abstract]   [Full Text] [Related]  

  • 19. [Efficiency of human papillomavirus vaccination--estimates based on Dutch cost effectiveness analyses].
    Westra TA; Daemen T; Postma MJ; Wilschut JC
    Ned Tijdschr Geneeskd; 2009; 153():A356. PubMed ID: 19930733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Latin America. Price is the main barrier to wider use of papillomavirus vaccine.
    Kaiser J
    Science; 2008 May; 320(5878):860. PubMed ID: 18487164
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.